全文获取类型
收费全文 | 5654篇 |
免费 | 356篇 |
国内免费 | 206篇 |
专业分类
耳鼻咽喉 | 45篇 |
儿科学 | 35篇 |
妇产科学 | 20篇 |
基础医学 | 235篇 |
口腔科学 | 75篇 |
临床医学 | 370篇 |
内科学 | 318篇 |
皮肤病学 | 91篇 |
神经病学 | 76篇 |
特种医学 | 135篇 |
外国民族医学 | 1篇 |
外科学 | 176篇 |
综合类 | 754篇 |
预防医学 | 393篇 |
眼科学 | 23篇 |
药学 | 2278篇 |
5篇 | |
中国医学 | 1001篇 |
肿瘤学 | 185篇 |
出版年
2024年 | 35篇 |
2023年 | 115篇 |
2022年 | 198篇 |
2021年 | 260篇 |
2020年 | 209篇 |
2019年 | 235篇 |
2018年 | 250篇 |
2017年 | 181篇 |
2016年 | 189篇 |
2015年 | 162篇 |
2014年 | 332篇 |
2013年 | 510篇 |
2012年 | 320篇 |
2011年 | 385篇 |
2010年 | 290篇 |
2009年 | 260篇 |
2008年 | 266篇 |
2007年 | 259篇 |
2006年 | 182篇 |
2005年 | 220篇 |
2004年 | 164篇 |
2003年 | 149篇 |
2002年 | 103篇 |
2001年 | 98篇 |
2000年 | 80篇 |
1999年 | 97篇 |
1998年 | 85篇 |
1997年 | 58篇 |
1996年 | 64篇 |
1995年 | 69篇 |
1994年 | 68篇 |
1993年 | 51篇 |
1992年 | 32篇 |
1991年 | 33篇 |
1990年 | 32篇 |
1989年 | 27篇 |
1988年 | 26篇 |
1987年 | 16篇 |
1986年 | 17篇 |
1985年 | 19篇 |
1984年 | 11篇 |
1983年 | 7篇 |
1982年 | 14篇 |
1981年 | 10篇 |
1980年 | 9篇 |
1979年 | 4篇 |
1977年 | 3篇 |
1976年 | 3篇 |
1974年 | 3篇 |
1972年 | 2篇 |
排序方式: 共有6216条查询结果,搜索用时 15 毫秒
1.
In forensic medicine, although various alcohols have been reported as indicators of decomposition in collected blood, no studies have examined short-chain fatty acids as indicators. In this study, the blood n-butyric acid concentration was quantified, and the association between n-butyric acid and decomposition was investigated to determine whether the detection of n-butyric acid could be a new indicator of decomposition. Among the forensic autopsies performed from 2016 to 2018 in our laboratory, the cases were divided into decomposed (n = 20) and non-decomposed (n = 20) groups based on macroscopic findings. Blood samples collected at the time of autopsy were derivatized with 3-nitrophenylhydrazine hydrochloride after solid-phase extraction. The n-butyric acid concentration was measured using liquid chromatography–tandem mass spectrometry. In addition, ethanol and n-propanol were measured using a gas chromatography-flame ionization detector. There was a significant difference (p < 0.01) in the concentrations of n-butyric acid between the decomposed and non-decomposed groups (0.343 ± 0.259 [0.030–0.973] and 0.003 ± 0.002 [0.001–0.007] mg/mL, respectively). In the decomposed group, n-butyric acid was detected at high concentrations, even in cases where n-propanol was low. These results suggest that n-butyric acid is more likely to be an indicator of blood decomposition than n-propanol. 相似文献
2.
3.
Chih-Wei Hsu Sheng-Yu Lee Yao-Hsu Yang Liang-Jen Wang 《The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP)》2020,23(10):653
BackgroundGeneric antidepressants are approved on the market based on evidence of bioequivalence to their brand-name versions. We aimed to assess whether generic antidepressants exert equal effectiveness as their brand-name counterparts for treating patients with depressive disorders.MethodsIn a nationwide, population-based cohort in Taiwan from 1997 through 2013, patients with a diagnosis of a depressive disorder aged between 18 and 65 years who were new users of antidepressant drugs were classified into either the brand-name group or the generic group. All patients were followed up until medication discontinuation or the end of the study period. We assessed the risk for hospitalization as a primary outcome and augmentation therapy, daily dose, medication discontinuation, or switching to another antidepressant as secondary outcomes.ResultsA total of 277 651 brand-name users (35.8% male; mean age: 41.2 years) and 270 583 generic users (35.8% male; mean age: 41.0 years) were divided into 10 different antidepressant groups (fluoxetine, sertraline, paroxetine, escitalopram, citalopram, venlafaxine, mirtazapine, moclobemide, imipramine, and bupropion). We found that patients treated with the generic form of sertraline, paroxetine, escitalopram, venlafaxine, mirtazapine, and bupropion demonstrated significantly higher risks of psychiatric hospitalization (adjusted hazard ratios ranged from 1.20–2.34), compared to their brand-name counterparts. The differences between brand-name antidepressants and their generic counterparts in secondary outcomes varied across different drugs.ConclusionsCompared to most generic antidepressants, brand-name drugs exhibited more protective effects on psychiatric hospitalization for depressive patients. These findings could serve as an important reference for clinicians when encountering patients with depressive disorder. 相似文献
4.
Algorithms based on deep neural networks (DNNs) have attracted increasing attention from the scientific computing community. DNN based algorithms are
easy to implement, natural for nonlinear problems, and have shown great potential to
overcome the curse of dimensionality. In this work, we utilize the multi-scale DNN-based algorithm (MscaleDNN) proposed by Liu, Cai and Xu (2020) to solve multi-scale
elliptic problems with possible nonlinearity, for example, the p-Laplacian problem.
We improve the MscaleDNN algorithm by a smooth and localized activation function.
Several numerical examples of multi-scale elliptic problems with separable or non-separable scales in low-dimensional and high-dimensional Euclidean spaces are used
to demonstrate the effectiveness and accuracy of the MscaleDNN numerical scheme. 相似文献
5.
6.
7.
Robbert-Jan Roozeman Lasse Murtomäki Kyösti Kontturi 《Journal of electroanalytical chemistry (Lausanne, Switzerland)》2005,575(1):9-17
A recently introduced setup to measure the dynamic interfacial tension of expanding drops was used to compare the adsorption behaviour of a series of lipids at the electrified water∣dichloroethane interface. Phospholipids with saturated carbon chains of different length (DMPC, DPPC, DSPC, DAPC, DBPC), an unsaturated phospholipid (DOPC) and an ethanolamine (DSPE) were compared. It was found that the adsorption decreases with increasing chain length. Also, the increase of the flow rate reduces the degree of adsorption effectively. On the timescale of the experiments, the DSPE, DAPC and DBPC adsorption showed no potential dependence, whereas the adsorption of DOPC was stronger than that of the saturated lipids. Adsorption was modelled using the Langmuir adsorption isotherm; the potential dependence of adsorption is discussed. 相似文献
8.
Gene delivery systems are designed to control the location of administered therapeutic genes within a patient's body. Successful in vivo gene transfer may require (i) the condensation of plasmid and its protection from nuclease degradation, (ii) cellular interaction and internalization of condensed plasmid, (iii) escape of plasmid from endosomes (if endocytosis is involved), and (iv) plasmid entry into cell nuclei. Expression plasmids encoding a therapeutic protein can be, for instance, complexed with cationic liposomes or micelles in order to achieve effective in vivo gene transfer. A thorough knowledge of pharmaceutics and drug delivery, bio-engineering, as well as cell and molecular biology is required to design optimal systems for gene therapy. This mini-review provides a critical discussion on cationic lipid-based gene delivery systems and their possible uses as pharmaceuticals. 相似文献
9.
Angel J. Amante Herwig-Ulf Meier-Kriesche Linda Schoenberg B. D. Kahan 《Transplant international》1997,10(3):217-222
The initial poor absorption of the corn oil-based, gel capsule oral formulation of cyclosporin (CyA) greatly limits its use
for inception of immunosuppressive therapy. Insufficient drug concentrations during the early post-transplant period predispose
to renal allograft rejection. The present study served to compare the time required to achieve therapeutic CyA concentrations
after de novo administration of the corn oil-based gel capsule (CyA-GC; n = 11) versus the microemulsion (CyA-ME; n = 11) formulation of CyA. During the 1st month after renal transplantation, patients underwent serial pharmacokinetic profiling
from which we obtained observed and dose-corrected values of several parameters. Although patients in neither the CyA-GC nor
the CyA-ME group adequately absorbed the drug during days 0–2, from day 3 to 4 patients in the CyA-ME group showed significantly
greater absorption than those in the CyA-GC group (P = 0.041). Patients in the CyA-ME group reached the 1st month target average concentration (Cav) values ( ≥ 550 ng/ml) earlier than those in the CyA-GC group and required significantly lower daily CyA doses (P = 0.018). We conclude that therapeutic CyA levels can be achieved more rapidly and with lower doses of the drug after de
novo administration of CyA-ME than with CyA-GC.
Received: 13 September 1996 Accepted: 7 January 1997 相似文献
10.
R. Schall F. O. Müller H. K. L. Hundt L. Duursema G. Groenewoud M. Van Dyk A. M. C. Van Schalkwyk 《Biopharmaceutics & drug disposition》1994,15(6):493-503
Four controlled-release nifedipine products were investigated in two clinical studies. In study 1, 22 healthy male volunteers took part in an open, multiple-dose, randomized, crossover study to determine the relative bioavailablity of two 10 mg controlled-release nifedipine tablet (Adalat® Retard, Bayer), administered 12 hourly, and one 20 mg controlled-release nifedipine tablet (Adalat® Retard, Bayer) administered 12 hourly. In study 2, 24 healthy male volunteers took part in an open, multiple-dose, randomized, three-period, crossover study to determine the relative bioavailability of (i) two 30 mg nifedipine gastro-intestinal therapeutic system (GITS) tablets (Adalat® XL, Bayer) administered once daily; (ii) one 60 mg nifedipine GITS tablet (Adalat® XL, Bayer) administered once daily; and (iii) one 20 mg plus one 10 mg nifedipine controlled-release tablet (Adalat® Retard, Bayer), administered 12 hourly. In both studies detailed pharmacokinetic data, in particular with respect to the controlled-release characteristics of the different formulations, were collected. Results of both studies indicate that all nifedipine products investigated are bioequivalent with respect to the extent of absorption of nifedipine. The nifedipine GITS products (Adalat® XL) have better controlled-release properties than the Adalat® Retard product, and are suitable for once-a-day administration. 相似文献